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Abstract
BACKGROUND: The availability of psychotic medications in primary health care in Indonesia is in a limited number. 
The center of psychiatric health-care provides varied types of medications. However, the quantities are limited, in 
which the second generation of psychotic drugs is relatively expensive. Common available drug medications are 
haloperidol and diazepam.
AIM: This study aims to investigate the difference scores of Positive and Negative Syndrome Scale (PANSS-EC) 
in psychotic agitation patients of haloperidol prescription and those who have been prescribed with haloperidol and 
diazepam injections at Prof. Dr. M. Ildrem Mental Hospital, Medan North Sumatera, Indonesia.
METHODS: This study involved 64 psychotic agitation patients who were divided into two groups. The first group 
was 32 patients who have been prescribed by 5 mg of haloperidol injections and the second group was 32 patients 
who have been injected by 5 mg of haloperidol and 10 mg of diazepam. The PANSS-EC score assessment was 
performed for 1 h due to the side effects of medication consumption.
RESULTS: A significant comparison in terms of the decreasing of PANSS-EC scores in psychotic agitation patients 
who have been injected by the combination of haloperidol and diazepam was confirmed during the assessment of 
30 and 60 min (p < 0.001). The extrapyramidal side effects in haloperidol group were found in two subjects, and 
the reinjections of combination therapy of haloperidol and diazepam were lower than those with one type of drugs 
medication, which, respectively, were accounted for 56.25% and 84.37%.
CONCLUSIONS: Combination therapy of haloperidol and diazepam had more accelerating effects in reducing 
agitation compared to those prescribed by only haloperidol.
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Introduction
The psychotic agitation procedural treatments 
must have been based on the principle of unrestrained 
practices to avoid human rights violations [1]. The 
restraining and isolation occasionally cannot be 
avoided due to their aggressiveness which is a common 
phenomenon due to the discontinuation of drugs 
consumptions [2]. In several cases, agitation can be 
controlled by non-pharmacological approach, such as 
verbal interventions and de-escalation; however, some 
individuals require pharmacological medications [3].
More than a half century, various 
pharmacological drugs and treatments to control 
agitation behaviors have been tested. At present, the 
most common psychotic medications are the first and 
second generation of antipsychotic (FGA) medications, 
and benzodiazepine, even the second-generation 
combinations are favored in treating agitation patients [4]. 
The FGA, which, in this case, is haloperidol, has been 
extensively used in a very long time in the treatments 
of psychotic agitation. The combination of antipsychotic 
drugs and benzodiazepine requires varied mechanisms 
by expecting augmentation process as well as avoiding 
complications due to high dosages of antipsychotic. 
The amnesic effects of benzodiazepine benefits to 
patients who have been suffering by tragic moments 
such as frequent medications, restraining, and isolation. 
Favorable combination in oral treatments is haloperidol 
(with the addition of procyclidine) and diazepam, whereas 
intramuscular treatments were performed by injecting 
haloperidol (with procyclidine) and lorazepam [6].
Haloperidol is an antagonist receptor of 
dopamine-2 which has minimal effects to vital sign, 
anticholinergic activities, antihistamine, and low 
interactions to any non-psychotic drugs. The side 
effects are extrapyramidal symptoms (EPSs) such as 
parkinsonism, dystonia, and akathisia, which can be 
treated by anticholinergic medications (diphenhydramine 
and benztropine), QTc prolongation-torsade de pointes 
(Tdp), particularly for intravenous injections, neuroleptic 
malignant syndrome, and catatonic reaction specifically 
in high dosages prescription [5], [6].
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Meanwhile, benzodiazepine drugs which are 
commonly prescribed in treating psychotic agitation 
are diazepam, lorazepam, clonazepam [6], and 
midazolam [7], [8]. Midazolam has higher superiority 
than that in haloperidol in controlling agitation, however, 
it is extremely sedative which is sleep-inducing effects. 
The clonazepam has limited efficacies in handling 
agitation so that it is not recommended. Lorazepam is 
benzodiazepine group which is favored in the treatment 
of agitation; however, in Indonesia, parenteral 
formulation is not available [7], [8], [9], [10].
A study conducted by Canon, in 2001, which 
involved 116 emergency units in Australia has reported 
that the common prescribed therapies were haloperidol 
(93%), midazolam (82%), and diazepam (59%). 
The same study also found that the prescription of 
benzodiazepine and one tranquilizer at least occurred 
in 97% of emergency units [11]. The prescription of 
intramuscular diazepam treatments is not considerably 
explored in clinical studies. This is probably due to 
the difficulties in pharmacokinetic issues related to its 
gluteal injections. However, no difficulties have been 
reported during the injection of IM deltoid, in which 
the absorption is quicker than that in IM gluteal [12]. 
Divoll et al., in 1983, have reported that the diazepam 
absorption was performed in a quick and complete way 
compared to those in IM deltoid injections [13], [14].
According to the Indonesian National 
Formularium, diazepam and midazolam must be 
available in primary and referral health-care facilities, 
while the oral lorazepam drugs availability is merely 
preserved by referral hospital. Nevertheless, the 
preservation of diazepam should have been in higher 
quantities in all health-care facilities. Due to the 
haloperidol and diazepam availability is sufficient which 
also has more affordable prices compared to the second 
generation of antipsychotic (unavailable of ampoule), a 
study is conducted to determine score differences in 
Positive and Negative Syndrome Scale (PANSS-EC) 
assessment [15] of psychotic agitation patients who 
have been prescribed by haloperidol and diazepam 
injections and only haloperidol injections.
Materials and Methods
Research design
This study is an open trial experimental study 
with pre- and post-test. The population is agitation 
psychotic patients who have visited the emergency unit 
of mental hospital of Prof. Dr. M. Ildrem, North Sumatera 
Province in the period of June 2019–September 2019. 
The samples collection was performed throughout 
non-probability sampling type with consecutive 
sampling. Due to limited reports regarding Indonesian 
patients, a preliminary study by recruiting 20 subjects 
divided into two groups, in which the number of study 
samples was obtained and was performed. Based on 
a previous study [16], with average deviations which 
were classified significant results for n = 3, 32 subjects 
were recruited for every groups (the first group was 
injected by haloperidol with the addition of diazepam, 
while the other group was prescribed only by the 
injection of haloperidol). This study has been agreed by 
the Research Ethical Committee of Medical Faculty of 
Universitas Sumatera Utara, Indonesia (No. 664/TGL/
KEPK FK USU-RSUP HAM/2019) which follows the 
Nuremberg Code and Helsinki Declaration.
Research subjects
The inclusion criteria in this study were male 
agitation psychotic patients (with PANSS-EC score for 
≥14 with subitem assessment score for ≥4), with the age 
of 18–40 years of old and normal body mass index (BMI). 
Meanwhile, the exclusion criteria were the patients 
who have been experiencing normal medical disorder 
and those who have drugs and alcohol abuse (except 
caffeine and nicotine) [17], [18], [19], [20], [21], [22].
Research procedure
Recruited subjects have followed the 
inclusion and exclusion criteria (with PANSS-EC 
baseline score assessment, body mass, and height 
measurements). Then, random allocation by following 
coins flipping was performed so that every subject 
had exact opportunity to be involved in the study. 
Next, medication injections were performed based on 
random groups; (1) First group: 5 mg of haloperidol, IM, 
in medius/lateral musculus gluteus and the injections of 
10 mg of diazepam, IM, in the deltoids musculus which 
is located on a third part of hands, and (2) Second 
group: 5 mg of injection, IM, medius/lateral musculus. 
During the injections, subjects that were agitated 
were restrained and isolated. Afterward, PANSS-EC 
assessments were carried out in 30 and 60 min, and 
calmed patients were carried out to the wards. The 
syndrome extrapyramidal side effects were examined 
by performing standard procedures in detecting the 
syndrome by the time of PANSS-EC assessment, in 
which confirmed syndromes in patients were injected 
by 10 mg of diphenhydramine and were excluded 
from the study. As this study was performed under on 
treatment analysis, excluded subjects were replaced 
by others [23].
In PANSS-EC assessment, suitability tests 
among researchers and interpreters were conducted. 
The analysis tests utilized numeric comparative tests 
(Bland Altman) due to numeric variable of scales that 
were measured. The results of analysis tests showed 
that limit of agreement was in 5 and 5 (−2.38–2.10). 
Therefore, it can be concluded that among observers, 
acceptable suitability/reliability was confirmed [24].
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Statistical data analysis
The data analysis was carried out using the 
Statistical Package for the Social Sciences software. 
The design of this study is numeric comparative 
measurements with unpaired groups, so normal 
data distribution was proceeded throughout general 
linear model + post hoc tests. However, abnormal 
data distribution was analyzed using Mann–Whitney, 
corrected repetition tests were performed. Normality 
data tests were conducted using Shapiro–Wilk tests 
since <50 samples were collected.
Results
Table 1 highlights categorical and numerical 
data. The categorical variables which are discussed are 
educations, occupations, and marital status, in which 
all of these three variables had categorical analytical 
comparative diagnosis with unpaired table of 2 × 2. 
From the test analysis which was performed, <5 or 
20% of expected count value was obtained so that Chi-
square test requirements were befitted. Subsequently, 
for table of 2 × 2, a suggested analysis was Chi-square 
with continuity correction. From the test analysis which 
was carried out, no confirmed significant difference of 
demographical characteristics in terms of educations 
(p > 0.439), occupations (p < 0.784), and marital status 
(p < 0.281) was found [23], [24]. From Table 1, it can 
be seen that the highest percentages of educations, 
occupations, and marital status were in primary and 
junior high school (62.5%), unemployment (70.3%), 
and non-marital status (68.7%), respectively.
Table 1: Demographical characteristics of psychotic agitation 
patients for both groups
Variables n (%) Group I 
(haloperidol+diazepam)
Group II 
(haloperidol)
p
Ages (years) 
Median (min-max)
32.5 (25.0–40.0) 36.0 
(25.0–40.0)
0.102*
Educations primary
Junior high 40.0 (62.5) 22.0 (55.0) 18.0 (45.0) 0.439**
≥Senior high 24.0 (37.5) 10.0 (41.7) 14.0 (58.3)
Occupation
Working 19.0 (29.6) 9.0 (47.4) 10.0 (52.6) 0.784**
Not working 45.0 (70.3) 23 (51.1) 22 (48.9)
Marital status
Married 20.0 (31.2) 8.0 (40.0) 12.0 (60.0) 0.281**
Not married 44.0 (68.7) 24.0 (54.5) 20.0 (45.5)
BMI
Median 
(min-max)
23.4 (20.5–24.8) 23.4 
(20.5–24.8)
0.979*
PANSS-EC base 
line scores
Mean ± SD 28.7 ± 2.8 28.4 ± 2.6 0.654***
*Mann–Whitney U-test, **Chi-square test, ***independent-sample t-test. PANSS-EC: Positive and Negative 
Syndrome Scale-Exited Components, BMI: Body mass index.
The numerical variables that are discussed 
in Table 1 are ages, BMI, and baseline PANSS-EC 
score. These three variables involve in unpaired groups 
numerical analytical comparative diagnosis. The 
analytical tests were performed by the time the normality 
data test by conducting Shapiro–Wilk test due to the 
number of samples was done. The Shapiro–Wilk tests for 
these three samples showed only baseline PANSS-EC 
scores were distributed normally with p > 0.05, whereas 
the ages and BMI were confirmed to be undistributed 
normal with p < 0.05. For undistributed normal data, 
transformation data were conducted using log function; 
however, unsuccessful transformation occurred which 
suggested to alternative tests for every variable [23], [24]. 
In age and BMI variables, the Mann–Whitney U-tests 
were carried out, and it can be seen that no significant 
differences were occurred between these two variables, 
with p = 0.102 and p = 0.979, respectively.
The PANSS-EC baseline scores, in which 
the data were distributed normally, unpaired t-test (t 
independent sample) was performed. From the test 
results, Levene’s variant test was 0.572 (>0.05) so 
that equal variances assumed was confirmed for both 
groups which accounted for 0.654 with mean difference 
for 0.313 and IK value for 95% in between −1.075 and 
1.700. Due to p < 0.05, it can be concluded that no 
significant difference was found [23], [24].
Tables 2 and 3 which display Shapiro–Wilk 
tests to the three numerical variables show normal 
data distribution with p < 0.05. Subsequently, repeated 
ANOVA with general linear model was conducted 
which was followed by post hoc pairwise comparisons 
(Bonferroni) analysis. The multivariate test results 
showed the value of significance <0.001 (<0/005), so 
it can be concluded that two different measurements 
were found in minimum. To perceive these differences, 
output pairwise comparisons that compared the first 
and second, first and third, and second and third 
measurements were carried out. The significance 
value for every comparison was <0.001 so that 
statistical conclusion can be drawn that remarkably 
significant decreasing of PANSS-EC score for the 
first group was obtained in the baseline in 30 and 
60 min. However, according to the classification that
Table 2: PANSS-EC scores of patients in Group I
PANSS-EC time n Average (± std) p
Baseline 32 28.72 ± 2.86 <0.001
30 min 32 15.97 ± 3.60
60 min 32 14.19 ± 3.62
Repeated ANOVA tests and post hoc analysis p<0.001. PANSS-EC: Positive and Negative Syndrome 
Scale- Exited Components.
has been determined in this study, minimal deviation 
score of PANSS-EC is considered to be significantly 
difference the value for 3. In clinical term, significant 
decreasing of PANSS-EC scores for both baseline, 
since their score was 28.72 ± 2.86–15.97 ± 3.60 for 
base line30 min, while for baseline 60 min for 28.72 
± 2.86–14.19 ± 3.62. However, in this study, it is not 
classified as significantly difference due to the scores of 
PANSS-EC in 30 and 60 min which accounted for 15.97 
± 3.60–14.19 ± 3.62 [23], [24].
Table 3: PANSS-EC scores of patients in Group II
PANSS-EC time n Average (± std) p
Baseline 32 28.41 ± 2.68 <0.001
30 min 32 20.25 ± 3.02
60 min 32 18.94 ± 2.92
Repeated ANOVA tests and post hoc analysis p<0.001. PANSS-EC: Positive and Negative Syndrome 
Scale-Exited Components.
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Table 4 of Shapiro–Wilk for three variables of 
three numerical data for every group displays normal 
data distribution with p > 0.05. Subsequently, repeated 
ANOVA test with general linear model in which the 
results of time interaction influenced multivariate 
test and PANSS-EC scores contributed to significant 
value for <0.001 (<0.005). These results implied to the 
different decreasing of PANS-EC scores convincingly 
in between two groups in all assessments. The results 
of multivariate tests have been confirmed by the 
parameter estimates that were obtained from p value, 
in which it was based on 0.654 of baseline, <0.001 in 
30 min, and <0.001 in 60 min. The significant value 
of 0.654 and the confident value of p from average 
deviation of assessment that passed the value of 
0 in the baseline were not analyzed since this is a 
clinical study. Nevertheless, it can be concluded that a 
significant decreasing of PANSS-EC scores was found 
in both groups in 30 and 60 min [23], [24].
Table 4: PANSS-EC scores of samples in both groups
PANSS-EC 
time
Average ± 
(std) Group I
Average ± 
(std) Group II
Difference (IK95%) p
Baseline 28.72 ± 2.86 28.41 ± 2.68 0.31 (−1.08–1.7) <0.001
30 min 15.97 ± 3.60 20.25 ± 3.02 −4.28 (−5.94–−2.61)
60 min 14.19 ± 3.62 18.94 ± 2.92 −4.75 (−6.39–−3.10)
PANSS-EC: Positive and Negative Syndrome Scale-Exited Components.
Discussion
Table 1 shows that the age variable was 
obtained in the first group for 32.5 and 36 for the second 
group. For educations, occupations, and marital 
status variables, both groups were mainly composed 
of subjects with primary-junior high educations, 
unemployment, and non-marital status. The BMI 
results for both groups had exact median scores with 
23.4 (minimum-maximum accounted for 20.5–24.8) 
and for baseline scores of PANSS-EC were 28.7 ± 2.8 
for haloperidol and diazepam injections group, while 
28.4 ± 2.6 for the only haloperidol group. Tables 2 and 3 
show the decreasing score of PANSS-EC for both 
groups, in which a significant value with p < 0.001 
was obtained. Meanwhile, Table 4 displays excessive 
injections of haloperidol with the addition of diazepam, 
and it can be seen that the combination of these drugs 
contributed to higher value compared to that from 
haloperidol only.
This study is also in accordance with Pilowsky 
et al., in London, 1992, involved 120 subjects for 60 min, 
in which onset tranquilization has been reported to 
have quicker effects with the addition of diazepam and 
haloperidol than those who consumed only diazepam 
or haloperidol with p < 0.03. Significantly speaking, 
19% of patients who have received intervention of 
a type of drug require another drugs intervention 
(p < 0.03), and 6% of these patients demand two 
additional drugs [25]. In 2016, another similar study was 
conducted by Korczak et al., which was a systematic 
review and meta-analysis in Australia for seven studies 
by recruiting 1135 patients experiencing quicker effects 
of drugs combinations within 15–20 min. The quicker 
sedative side effects (risk ratio [RR] = 1.31, p < 0.001) 
were experienced by the samples from combination 
therapy of drugs compared to those who consumed 
benzodiazepine, antipsychotic medications, and their 
combinations even though the consumptions of both 
therapies were in smaller dosages and frequencies 
(RR = 0.49, p < 0.001 dan RR = 0.64, p = 0.002) [4].
As a comparative study, Bak et al., in 2019, 
have conducted a systematic review study and meta-
analysis of 53 53 studies with total of 17 types of 
drugs and 8829 subjects. This study has reported 
varied reduction of PANSS-EC score after 2 h of 
dosages interventions either in single or combination. 
PANSS-EC scores decreasing caused by lorazepam, 
haloperidol, haloperidol and promethazine, haloperidol 
and midazolam, levomepromazine, aripiprazole, 
olanzapine, risperidone, ziprasidone, loxapine 
inhalation, and placebo were 7 points, 7–8 points, 
15 points, 8–10 points, 15 points within 90 min, 5–6 
points for older subjects, 7–8 points with one exception 
of smaller reduction points, 7–10 points, 7–8 points 
that one study has reported the decrease up to 
14 points, 3–15 points, 9–11 points, and 2–6 points, 
respectively [8].
Based on onset of efficacy, Zun (2017) in 
Chicago has reported consistent agitation improvement 
in terms of the decreasing of PANSS-EC to be caused 
by combination of 10 mg of IM olanzapine and 
10–20 mg of IM ziprasidone for 15 min. In contrast to 
5–10 mg IM haloperidol (30–60 min), even though this 
was combined by 2 mg of IM lorazepam. Nevertheless, 
a study has reported a decreasing in agitation within 
15 min by utilizing 7.5 of IM haloperidol per day, as well 
as the utilization of IM aripiprazole with placebo control 
that has been reported to decrease PANSS-EC scores 
significantly within 45–60 min (initial assessments were 
performed in minutes of 15–30) [20].
In this study, the results obtained showed 
that several patients were recommended to receive 
reinjections by 60 min. For haloperidol combined with 
diazepam, 18 individuals (56.25%) and 27% (84.37%) 
for haloperidol only group were advised. A study 
conducted by Pilowsky et al. (1992), it has been reported 
that 19% of patients receiving one type of drug required 
one additional drug and two types of additional drugs 
for 6% of patients [25]. On the other hand, additional 
consumption of antipsychotic and their combination 
also has been reported in significantly reducing the 
sedative effects compared to those in benzodiazepine 
only (RR = 0.49, p < 0.001 and RR = 0.64, p = 0.002) [4]. 
This difference could have been explained due to the 
average baseline score of PANSS-EC (28.72 ± 2.86 
and 28.41 ± 2.68), and field observations have shown 
that medical treatments were performed given that 
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the patients have started agitation behaviors such as 
attacking and damaging.
In this study, no meaningful side effects 
were confirmed. Two subjects (6.25%) experienced 
the extremely minimal EPS side effects so that 
no necessary treatments were required which 
were probably caused by the minimum dosages 
of haloperidol. Every individual displayed actual 
differences under the treatment of optimal dosage of 
antagonist receptor dopamine. As an example, several 
patients experienced difficulties to tolerate 1 mg of 
haloperidol side effects, whereas the others tolerated 
50 mg of haloperidol without experiencing the side 
effects. Determining the perfect dosages for antagonist 
receptor dopamine is essentially required, however, it is 
challenging [26]. While, several studies have reported 
a few side effects, including respiratory complication 
in 2 subjects (2%) and cardiovascular conditions for 
3 subjects (3%). Respiration condition occurred to the 
flow of 60 mg of haloperidol and 80 mg of diazepam 
into bolus intravenous, in which haloperidol side effects 
have been reported to be EPS in 6–55% of cases, 
acute dystonia for 0–17% of cases, and akathisia for 
8–46% of cases [25]. The side effects in cardiovascular 
condition have been reported to be QT elongation 
which can increase the risks of arrhythmia, caused 
by haloperidol for 0–6% of cases and lorazepam for 
7% of cases, while in the use of benzodiazepine, no 
side effects were found [25]. However, hypotension 
side effects have been reported for 0–17% due to the 
consumption of haloperidol [8].
Although studies have been performed as 
open trial conditions including randomized controlled 
trials, no confirmed evidences as well as placebo can be 
considered as a gold standard in terms of effectiveness 
and safety of drugs types. The decision of determining 
and administering the antipsychotics is the authority of 
the doctors-patients [18], [27], [28]. This study is the 
first clinical study involving agitation patients in North 
Sumatera, and not dropout patients were obtained. 
As this study was carried out in an open trial without 
multicenter investigation which observed within 1 h only, 
further investigation in multicenter as well as various 
time is required to be conducted in future [29], [30], [31].
Conclusions
Based on age homogeneity, educations, 
occupations, marital status, BMI, and baseline 
PANSS-EC scores, the combination therapy of 
haloperidol and diazepam showed more promising 
results compared to those who only prescribed by 
haloperidol in the treatments of psychotic agitation 
patients. Moreover, no significant side effects were 
observed which indicated no further and necessary 
treatments due to lower dosages of combined 
antipsychotics.
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